Title |
Evaluation of the adverse event profile and pharmacodynamics of toceranib phosphate administered to dogs with solid tumors at doses below the maximum tolerated dose
|
---|---|
Published in |
BMC Veterinary Research, September 2013
|
DOI | 10.1186/1746-6148-9-190 |
Pubmed ID | |
Authors |
Luis Feo Bernabe, Roberta Portela, Sandra Nguyen, William C Kisseberth, Michael Pennell, Mark F Yancey, Cheryl A London |
Abstract |
The receptor kinase inhibitor toceranib phosphate (Palladia) was approved for use in dogs in 2009 using a dose of 3.25 mg/kg administered every other day. Preliminary data suggests that lower doses of toeceranib may be associated with a reduced adverse event profile while maintaining sufficient drug exposure to provide biologic activity. The purpose of this study was to determine the Cmax of toceranib in dogs with solid tumors receiving 2.5-2.75 mg/kg every other day and to document the adverse events associated with this dose rate. Secondary objectives included determination of plasma VEGF concentrations in treated dogs and response to therapy. |
X Demographics
Geographical breakdown
Country | Count | As % |
---|---|---|
United States | 2 | 22% |
Italy | 1 | 11% |
Spain | 1 | 11% |
Argentina | 1 | 11% |
Unknown | 4 | 44% |
Demographic breakdown
Type | Count | As % |
---|---|---|
Members of the public | 8 | 89% |
Practitioners (doctors, other healthcare professionals) | 1 | 11% |
Mendeley readers
Geographical breakdown
Country | Count | As % |
---|---|---|
United States | 1 | <1% |
Unknown | 120 | 99% |
Demographic breakdown
Readers by professional status | Count | As % |
---|---|---|
Other | 18 | 15% |
Student > Master | 18 | 15% |
Researcher | 15 | 12% |
Student > Postgraduate | 14 | 12% |
Student > Doctoral Student | 6 | 5% |
Other | 22 | 18% |
Unknown | 28 | 23% |
Readers by discipline | Count | As % |
---|---|---|
Veterinary Science and Veterinary Medicine | 57 | 47% |
Medicine and Dentistry | 22 | 18% |
Agricultural and Biological Sciences | 6 | 5% |
Psychology | 2 | 2% |
Biochemistry, Genetics and Molecular Biology | 1 | <1% |
Other | 4 | 3% |
Unknown | 29 | 24% |